Bradley P. Knight, MD, FACC, FHRS

Letter from the Editor

Reducing the Rate of Serious Adverse Events in the Cardiac Electrophysiology Laboratory From 2% to 1%

07/25/2024

It is unrealistic to expect zero complications from an invasive procedure. It is also important to learn that trying to lower the rate of serious adverse events from 2% to 1% in the EP lab can require much more than twice the effort.

It is unrealistic to expect zero...

07/25/2024

EP Lab Digest

Letter from the Editor

Are Disease-Modifying Treatments on the Horizon for Patients With Arrhythmogenic Right Ventricular Cardiomyopathy?

07/02/2024

Bradley P. Knight , MD, FACC, FHRS;

Gene therapy targeting the underlying desmosomal mutation and approaches to prevent myocardial fibrosis independent of the specific genetic defect by increasing cardiac levels of FGF21 may be on the horizon for patients with ARVC.

Gene therapy targeting the...

07/02/2024

EP Lab Digest